Lilly’s triple agonist shows bariatric surgery-like weight loss results
BioSpace
Lilly met analysts' sky-high expectations with 28.3% weight loss over 80 weeks for the triple hormone receptor agonist retatrutide in a highly anticipated readout on Thursday.
pharminent
May 21, 2026 (Last updated: May 21, 2026)
BioSpace
Lilly met analysts’ sky-high expectations with 28.3% weight loss over 80 weeks for the triple hormone receptor agonist retatrutide in a highly anticipated readout on Thursday.
